Aspirin resistance: A fact or a myth?

Experimental and Clinical Cardiology

Volumn 10, Issue 1, 2005, Pages 17-20

  Rao, Gundu H R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Aspirin; Aspirin resistance; Cox inhibitors; Cyclooxygenase; Nonresponders; Stroke; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; IBUPROFEN; PROSTAGLANDIN G; PROSTAGLANDIN H; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ARACHIDONIC ACID METABOLISM; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEATH; DIAGNOSTIC PROCEDURE; DRUG ACTIVITY; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG SENSITIVITY; EXTRACELLULAR MATRIX; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; PATHOGENESIS; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT FAILURE; VASCULAR DISEASE;

EID: 18144390229     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Kwan HC, Bowie EJW. Thrombosis. Philadelphia: WB Saunders Co, 1982.
2. Hallam TJ, Sanchez A, Rink TJ. Stimulus-response coupling in human platelets. Changes evoked by platelet-activating factor in cytoplasmic free calcium monitored with the fluorescent calcium indicator quin2. Biochem J 1984;218:819-27.
3. Zucker MB, Nachimas VT. Platelet activation. Arteriosclerosis 1985;5:2-18.
4. Berridge MJ. The molecular basis of communication within the cell. Sci Am 1985;253:142-52.
5. Holmsen H. Platelet metabolism and activation. Semin Hematol 1985;22:219-40.
6. Siess W. Molecular mechanisms of platelet activation. Physiol Rev 1989;69:58-178.
7. Rao OH. Physiology of blood platelet activation. Indian J Physiol Pharmacol 1993;37:263-75.
8. Rao GH. Signal transduction, second messengers, and platelet function. J Lab Clin Med 1993;121:18-20.
9. Rao GH. Signal transduction, second messengers, and platelet pharmacology. Pharmacol 1994;13:39-44.
10. Packham MA. Role of platelets in thrombosis and hemostasis. Can J Physiol Pharmacol 1994;72:278-84.
11. Rao GH. Clinical relevance of platelet research in thrombosis and hemostasis. Indian J Progr Cardiovasc Sci 1996;3:21-4.
12. Rao GH, Rao AT. Pharmacology of platelet activation-inhibitory drugs. Indian J Physiol Pharmacol 1994;38:69-84.
13. Rao GH, White JG. Comparative pharmacology or cyclooxygenase inhibitors on platelet function. Prostaglandins Leukot Med 1985;18:119-31.
14. Rao GH, Rao AS. Aspirin in ischemic heart disease - an overview. Indian Heart J 1993;45:73-9.
15. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
16. Macchi L, Christiaens L, Brabant S, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002;107:45-9.
17. Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schror K. Towards a definition of aspirin resistance: A typological approach. Platelets 2002;13:37-40.
18. Howard PA. Aspirin resistance. Ann Pharmacother 2002;36:1620-4.
19. Yilmaz MB, Balbay Y, Korkmaz S. Aspirin resistance. Anadolu Kardiyol Derg 2004;4:59-62.
20. Tarjan J, Salamon A, Jager R, et al. The rate of acetylsalicylic acid non-repondents among patients hospitalized for acute coronary disease, previously undergoing secondary salicylic acid prophylaxis. Orv Hetil 1999;140:2339-43.
21. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-5.
22. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness by PFA-100 in patients with coronary artery disease. Thromb Res 2002;108:37-42.
23. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-5.
24. Cotter G, Shemesh E, Zehavi M, et al. Lack of aspirin effect: Aspirin resistance or resistance to taking aspirin? Am Heart J 2004;147:293-300.
25. Andrew Pollack. For some aspirin may not help. New York Times. July 20, 2004.
26. Zucker MB, Peterson J. Inhibition of adenosine diphosphate-induced secondary aggregation and other platelet functions by acetylsalicylic acid ingestion. Proc Soc Exp Biol Med 1968;127:547-51.
27. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5.
28. Rao GH, Reddy KR, White JO. Low dose aspirin, platelet function and prostaglandin synthesis: Influence of epinephrine and alpha adrenergic blockade. Prostaglandins Med 1981;6:485-94.
29. Rao GH, Johnson GJ, White JG. Influence of epinephrine on the aggregation response of aspirin-treated platelets. Prostaglandins Med 1980;5:45-48.
30. Rao GH, Reddy KR, White JG. Modification of human platelet response to sodium arachidonate by membrane modulation. Prostaglandins Med 1981;6:75-90.
31. Rao GH, Gerrard JM, Witkop CJ, White JG. Platelet aggregation independent of ADP release or prostaglandin synthesis in patients with Hermansky-Pudlak syndrome. Prostaglandins Med 1981;6:459-72.
32. Rao GH, White JG. Role of arachidonic acid metabolism in human platelet activation and irreversible aggregation. Am J Hematol 1985;19:339-47.
33. Rao GH, Radh E, Johnson GJ, White JG. Enteric-coated aspirin, platelet cyclooxygenase activity and function. Prostaglandins Leukot Med 1984;13:341-7.
34. Rao GH, Radha E, White JG. Irreversible platelet aggregation does not depend on lipoxygenase metabolites. Biochem Biophys Res Commum 1985;131:50-7.
35. Rao GH, Escolar G, White JG. Epinephrine reverses the inhibitory influence of aspirin on platelet-vessel wall interactions. Thromb Res 1986;44:65-74.
36. Folts JD, Rowe GO, Rao GH. Problem with aspirin as antithrombotic agent in coronary artery disease. Lancet 1988;1:937-8.
37. Rao GH, White JG. Influence of various doses of aspirin (in vivo) on platelet arachidonic acid metabolism (ex vivo) and function. Prostaglandins Leukot Essent Fatty Acids 1994;51:63-7.
38. Rao GH, White JG. Epinephrine potentiation of arachidonate-induced aggregation of cyclooxygenase-deficient platelets. Am J Hematol 1981;11:355-66.
39. Swier P, Mohammad SF, Olsen DB, Kolff WJ. A comparison of the antiplatelet effect of aspirin on human and bovine platelets. ASAIO Trans 1989;35:205-208.
40. Rao GH, Ericson DG, Weiss DJ, Parks PG, White JG. Influence of aspirin and carbacyclin on bovine platelet function. ASAIO J 1992;38:830-4.
41. Rao GH, Johnson GG, Reddy KR, White JG. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis 1983;3:383-8.
42. Williams B. White; Cardiovascular effects of cox-2 specific inhibitors. New perspectives on atherosclerosis: A CME accredited newsletter. ACC annual session, 2004.
43. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.